Ligand Pharmaceuticals (NASDAQ: LGND): Appendix
Lemelson Capital further increases short stake and reaffirms 100% downside risk in Ligand Pharmaceuticals (NASDAQ: LGND), ancillary applications for Promacta® and Kyprolis® not commercially viable, Duavee® sales remain immaterial
A PDF version of the report is availablehere.
- Read 18694 times